CA2393861A1 - Vaccins polynucleotidiques exprimant la proteine nef de vih-1 optimisee par codons et proteine nef de vih-1 modifiee - Google Patents

Vaccins polynucleotidiques exprimant la proteine nef de vih-1 optimisee par codons et proteine nef de vih-1 modifiee Download PDF

Info

Publication number
CA2393861A1
CA2393861A1 CA002393861A CA2393861A CA2393861A1 CA 2393861 A1 CA2393861 A1 CA 2393861A1 CA 002393861 A CA002393861 A CA 002393861A CA 2393861 A CA2393861 A CA 2393861A CA 2393861 A1 CA2393861 A1 CA 2393861A1
Authority
CA
Canada
Prior art keywords
nef
dna
seq
glu
hiv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002393861A
Other languages
English (en)
Inventor
John W. Shiver
Xiaoping Liang
Tong-Ming Fu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2393861A1 publication Critical patent/CA2393861A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • AIDS & HIV (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des compositions pharmaceutiques qui comprennent des vaccins ADN Nef de VIH ainsi que la production et l'utilisation de ces vaccins ADN. Les vaccins ADN à base de nef selon l'invention sont administrés par introduction directe dans les tissus d'un vertébré vivant, de préférence chez un homme et expriment la protéine Nef de VIH ou des parties appropriées du point de vue biologique de cette dernière, pour induire une réponse immunitaire des cellules qui reconnaît de manière spécifique le virus de l'immunodéficience humaine (VIH-1). Les molécules d'ADN qui comprennent le cadre de lecture ouvert de ces vaccins ADN sont des molécules d'ADN de synthèse qui codent une protéine Nef optimisée par codons et des dérivés de la protéine Nef de VIH-1 optimisée, y compris les modifications de nef comprenant les peptides principaux du terminal amino, l'élimination du site de myristylation du terminal amino, et/ou la modification du motif dileucine de Nef. Ces modifications peuvent produire des caractéristiques de type sauvage de Nef, telles que la myristylation et la régulation négative de l'hôte CD4.
CA002393861A 1999-12-17 2000-12-15 Vaccins polynucleotidiques exprimant la proteine nef de vih-1 optimisee par codons et proteine nef de vih-1 modifiee Abandoned CA2393861A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17244299P 1999-12-17 1999-12-17
US60/172,442 1999-12-17
PCT/US2000/034162 WO2001043693A2 (fr) 1999-12-17 2000-12-15 Vaccins polynucleotidiques exprimant la proteine nef de vih-1 optimisee par codons et proteine nef de vih-1 modifiee

Publications (1)

Publication Number Publication Date
CA2393861A1 true CA2393861A1 (fr) 2001-06-21

Family

ID=22627710

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002393861A Abandoned CA2393861A1 (fr) 1999-12-17 2000-12-15 Vaccins polynucleotidiques exprimant la proteine nef de vih-1 optimisee par codons et proteine nef de vih-1 modifiee

Country Status (5)

Country Link
EP (1) EP1242441A4 (fr)
JP (1) JP2003516741A (fr)
AU (1) AU782193B2 (fr)
CA (1) CA2393861A1 (fr)
WO (1) WO2001043693A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2487300A (en) 1998-12-31 2000-07-31 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
CA2378539A1 (fr) 1999-07-06 2001-01-11 Merck & Co., Inc. Vaccin contre le vih comprenant un adenovirus vehiculant le gene gag
CA2398816A1 (fr) 2000-02-04 2001-08-09 Duke University Vaccin contre le virus de l'immunodeficience humaine
US6733993B2 (en) 2000-09-15 2004-05-11 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications
AU2002320314A1 (en) 2001-07-05 2003-01-21 Chiron, Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
AU2002362368B2 (en) * 2001-09-20 2006-09-21 Glaxo Group Limited HIV-gag codon-optimised DNA vaccines
ES2560449T3 (es) 2004-05-28 2016-02-19 Oryxe Una mezcla para administración transdérmica de compuestos de peso molecular bajo y alto
GB0417494D0 (en) 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
MX2007003214A (es) * 2004-09-17 2007-10-11 Centelion Formulaciones liquidas estables de adn plasmidico.
EP2185195A2 (fr) 2007-08-16 2010-05-19 Tripep Ab Plate-forme immunogène
PL229124B1 (pl) 2015-02-10 2018-06-29 Inst Biochemii I Biofizyki Polskiej Akademii Nauk Szczepionka DNA skierowana przeciwko wirusowi grypy H5N1, zmodyfikowana sekwencja nukleotydowa oraz zastosowanie zmodyfikowanej nukleotydowej sekwencji do wytwarzania szczepionki

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851813A (en) * 1990-07-12 1998-12-22 President And Fellows Of Harvard College Primate lentivirus antigenic compositions
WO2002022080A2 (fr) * 2000-09-15 2002-03-21 Merck & Co., Inc. Vaccins adenoviraux de premiere generation evolues, exprimant les proteines gag, pol et nef du vih-1 a optimisation des codons et leurs modifications

Also Published As

Publication number Publication date
EP1242441A4 (fr) 2004-04-14
AU782193B2 (en) 2005-07-07
WO2001043693A2 (fr) 2001-06-21
WO2001043693A3 (fr) 2002-02-21
AU2581001A (en) 2001-06-25
EP1242441A2 (fr) 2002-09-25
JP2003516741A (ja) 2003-05-20

Similar Documents

Publication Publication Date Title
EP0969862B1 (fr) Genes synthetiques du gag hiv
AU729231B2 (en) Synthetic HIV genes
JP4805511B2 (ja) Ｈｉｖに対する免疫応答における改善、または免疫応答に関する改善
US20060018881A1 (en) Coordinate in vivo gene expression
CA2258568A1 (fr) Vaccins comprenant des genes de synthese
US20030229214A1 (en) Vaccines comprising synthetic genes
KR20070041765A (ko) Ｈｉｖ-감염의 예방 및 치료를 위한 백신
JP2009039116A (ja) 抗原性ｃ型ｈｉｖポリペプチドをコードするポリヌクレオチド、ポリペプチドおよびそれらの使用
US20040180329A1 (en) Synthetic HIV gag genes
US20040191269A1 (en) Polyvalent, primary HIV-1 glycoprotein DNA vaccines and vaccination methods
SK287382B6 (sk) Očkovacia kompozícia
WO2011103417A2 (fr) Vecteurs exprimant des antigènes du vih et le gm-csf et procédés associés destinés à générer une réponse immunitaire
JP2013146270A (ja) 抗原性ｂ型ｈｉｖポリペプチドをコードするポリヌクレオチド、そのポリペプチドおよびそれらの使用
US6995008B1 (en) Coordinate in vivo gene expression
JP2004537303A (ja) 抗原性ｂ型ｈｉｖポリペプチドおよび／または抗原性ｃ型ｈｉｖポリペプチドをコードするポリヌクレオチド、それらのポリペプチドおよびそれらの使用
CA2393861A1 (fr) Vaccins polynucleotidiques exprimant la proteine nef de vih-1 optimisee par codons et proteine nef de vih-1 modifiee
EP2021356B1 (fr) Vaccin contre le vih
EP1670504A1 (fr) Vaccins contenant la proteine tat du vih en tant qu'adjuvant destine a ameliorer la reponse de lymphocytes t cytotoxiques
CA2395429A1 (fr) Vaccins polynucleotidiques exprimant le gene pol du vih-1 a optimisation des codons et le gene pol du vih-1 modifie
KR20230087583A (ko) 항원을 mhc-ii 경로로 전달하고 숙주에서 cd4+ 및 cd8+ t-세포 반응을 유도하는 새로운 세대의 렌티바이러스 벡터
US20170107260A1 (en) Mosaic hiv-1 sequences and uses thereof
US20030087225A1 (en) Synthetic HIV genes
Human et al. Progress in Gene Therapy: Basic and Clinical Frontiers, pp. 361-386 R. Bertolotti et al.(Eds)© VSP 2000
CZ276699A3 (cs) Syntetické GAG geny HIV
MXPA98006842A (en) Synthetic genes of

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead